Acutaas Chemicals Ltd Q1 FY2023 Concall Summary

Key Takeaways

• Pharma resilience, specialty ambition: Revenue grew 16% YoY with pharma intermediates up 15% despite industry softness, while the company laid groundwork for specialty chemicals and electrolytes to reshape the mix.
• Gross margin surged, EBITDA lagged: Gross margin jumped 572 bps YoY to 48.8% on mix and cost measures, but elevated energy and freight kept EBITDA margin flat sequentially at 18.1%.
• Electrolyte additives are the big bet: Two products are sampling globally, a land parcel is acquired, and management targets 10% of a \$2 bn market by 2028, with first revenue possible in Q4 FY23.
• Import substitution is the specialty engine: Two agrochemical molecules and one pharma molecule are in pilot or sampling, with commercialization starting in H2 FY23 and a target of 20–25% revenue contribution in 3–4 years.
• What to watch next quarter: Whether the coal boiler commission delivers the promised energy cost step-down, whether electrolyte approvals convert to orders, and whether the guided sequential margin uptick actually begins.

Pharma Intermediates: The Stable Base

• Volume-led growth: More than 90% of the 15% YoY pharma growth came from volume, not price or mix, reflecting sustained demand for the company's molecules.
• Chronic therapy insulation: The portfolio is concentrated in chronic (daily dose) therapies rather than acute treatments, providing demand stability even when broader pharma softens.
• Top molecule concentration: Trazodone alone contributed 21% of revenue, Entacapone 7.69%, and Dolutegravir 6%, with the latter underperforming due to lower tender issuance this year.
• Pipeline replenishment: Apixaban and Darolutamide are showing good potential, and Sitagliptin has begun receiving regular orders of several tons, broadening the base beyond the top three.
• Preferred supplier status: The company is the first choice for pharma sourcing due to its FDA-approved facility and strong documentation, giving it order-book visibility for the 20–25% top-line growth aspiration in FY23.

Nareshkumar Patel: "Luckily, we are not in an acute business, we are more in a chronic business where there is always a daily demand for doses."

Electrolyte Additives: The Optionality Bet

• Products disclosed: The two electrolyte additives are vinylene carbonate (final approval stage) and fluoroethylene carbonate (market sampling stage), both developed in-house.
• Geopolitical tailwind: European, Japanese and Korean battery manufacturers want a supply source outside China, creating a direct advantage for the company's entry.
• Sampling progress: Samples are approved in China and circulating in Europe; engagement is underway with customers in Korea and India.
• Raw material independence: Neither electrolyte depends on China for raw materials; one input is imported from Europe, and the process uses potassium chloride (readily available in India) rather than fluorine chemistry.
• Patent positioning: A patent application for the two electrolytes is under write-up but not yet filed, as management wanted to secure market positioning first.
• Capacity readiness: Current Jhagadia unit capacity is sufficient for initial demand; a dedicated plant will be built on the newly acquired Sachin, Surat land parcel if traction materializes, with expansion possible in 2024 or 2025.
• Revenue timing: Management expects to see some revenue from electrolyte additives in Q4 FY23, though this is excluded from the base 25% FY23 growth guidance.

Nareshkumar Patel: "According to the reports we had from the professionals, they are expecting \$2 billion of the revenue of this molecule in the year 2028 and we are expecting to capture 10% from that."

Specialty Chemicals: The Growth Pivot

• Import-substitute pipeline: Two new agrochemical products are in the sampling stage, and 2-Cyanophenol has moved to pilot stage, with commercialization expected in H2 FY23.
• Pharma import substitute: An anti-inflammatory molecule currently imported from China is in pilot stage; full potential is expected in FY24, and the name will be disclosed upon commercial order.
• Strategic revenue target: Management aims to bring specialty chemicals to roughly 35% of total revenue in the next 2–3 years, driven by high-volume growth from import-substitute products.
• Import-substitute contribution: The basket is expected to contribute 5–10% of revenue annually, reaching 20–25% in 3–4 years, with large volumes and values achievable through better technology, chemistry and yield.
• Margin catch-up ambition: Specialty segment margins are targeted to improve by 100–200 bps every quarter to close the gap with pharma margins.
• 2-Cyanophenol catalyst: Patent expiry on the final API (held by Syngenta) is expected in the next couple of years, after which demand could grow 2x–3x; management does not know the exact expiry date.

Nareshkumar Patel: "Import substitutes is mainly in our specialty chemical segments because we can get large volume and large value as well. We can dominate that through better technology, better chemistry and better yield, which makes us competitive against companies based outside India."

Margins: Gross Up, EBITDA Held Back

• Gross margin leap: Gross margin reached 48.8%, up 572 bps YoY and 467 bps QoQ, driven by better product mix, cost optimization, process improvement, new technology, and the ability to pass on incremental costs to customers.
• EBITDA margin stuck: EBITDA margin remained at 18.1%, flat QoQ and down from 19.5% YoY, because high energy prices and elevated freight costs offset the gross margin gains, and the specialty chemical business carried lower EBITDA margins.
• Energy cost drag: Unit 2 at Gujarat Organics used gas and another unit used furnace oil, both suboptimal fuels; conversion cost and electricity cost rose 5–6%, and freight on imports rose 2–2.5%.
• Coal boiler remedy: Environmental clearance has been obtained to replace furnace oil with coal at the Jhagadia plant; new coal boilers are procured and under installation, with commissioning targeted this quarter for the GOL plant.
• Sequential margin path: Management expects incremental revenue each quarter to impact variable costs and lower fixed costs, making a margin improvement from 18% toward 20–22% possible, with full-year EBITDA margin improving 100–200 bps over FY22, and the target is to eventually get to 22-23%.
• Cost normalization timeline: Operating costs as a percentage of sales are expected to go down and normalize in Q3 or Q4, with freight normalizing in the next couple of months.

Nareshkumar Patel: "We want to go to our normalized margin of FY21. That is our target... Our target is to eventually get to 22-23%."

Gujarat Organics: Integration Grind

• Utilization stalled: Utilization remained at 40%, unchanged from the last couple of quarters, as the company works through Phase 2 of the integration.
• Phase 1 done, Phase 2 underway: Centralizing and consolidating production from two locations to one was completed in Q4FY22; the current phase focuses on process improvements, operational efficiency, yield improvement and technology mitigation for each molecule, targeted for completion by Q2FY23.
• Phase 3 ambition: After process improvements finish, the focus will shift to dominating the market by putting in large-scale production.
• Methyl Salicylate upgrade: Conversion from batch to continuous process is underway with equipment ordered and installation in progress; once installed, capacity will be large and provide cost leverage.
• Utilization outlook: Expected to rise to 50% this year, though continuous flow operations replacing batch processes make precise utilization forecasts difficult.

Guidance & Commitments

Key Metrics